Sep 25, 2017 · Some women have breast tumors with higher levels of a protein known as HER2/neu – these are called HER2-positive breast cancers. What is HER2/neu and what does it mean? HER2/neu (often just shortened to HER2) is a growth-promoting protein Last Revised: September 25, 2017. HER2 is a protein that causes breast cancer cells to grow, and can cause aggressive breast cancer. Read about survival rates, treatments, and more.Author: Robin Madell.
Apr 02, 2019 · Knowing the HER2 status of breast cancer helps determine which treatment is best for you. Find out what you need to know about these tests and how to ensure the best outcome.Author: Kimberly Holland. Oct 19, 2018 · HER2 is a gene that codes for a protein present on the surface of cells. A healthy breast cell has two copies of the HER2 gene. In approximately 30 percent of breast cancers, breast cancer cells have more than two copies of that gene, and this leads to an over-production of the HER2 protein. As a result, the affected cells grow and divide much too quickly.
What Is HER2-Negative Breast Cancer? HER2-negative breast cancer means tests show no abnormality in the human epidermal growth factor receptor 2 gene. Normally present in breast tissue, HER2 receptors help control how breast cells grow and divide. When the gene stops functioning properly, breast cells begin to multiply in an uncontrolled way. Some breast cancer cells need estrogen and/or progesterone (hormones produced in the body) to grow. These cancer cells have special proteins inside, called hormone receptors. HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.
Dec 20, 2012 · Human epidermal growth factor receptor 2 (HER2) is overexpressed in around 20–30% of breast cancer tumors. It is associated with a more aggressive disease, higher recurrence rate, and increased mortality. Trastuzumab is a HER2 receptor blocker that has become the standard of care for the treatment of HER2 positive breast cancer. Jan 01, 2010 · Patients and Methods. Two thousand ninety-one women with metastatic breast cancer diagnosed from 1991 to 2007, with known HER2/neu status and who had not received trastuzumab in the adjuvant setting, were identified. Disease was classified into the following three groups: HER2/neu negative, HER2/neu positive without first-line trastuzumab treatment, and HER2/neu positive with first Cited by: 723.